Wegovy HCP Overview: Guiding Patients Towards Semaglutide Treatment

Is this patient clinically eligible under the UK licence?

The first decision is always eligibility. The MHRA licence covers adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition such as hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease. For clinical practice, lower BMI thresholds (2.5 kg/m² below the standard figures) apply for patients from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK guidance.

NICE's TA875 recommendation is narrower than the licence: it targets adults with a BMI of 35 or above and at least one weight-related comorbidity, treated within a specialist weight management service offering multidisciplinary support. BMI thresholds in Scotland, Wales and Northern Ireland are set independently, so check local guidance for patients in those nations. A patient who meets the licensed criteria but not the NICE criteria may still access treatment privately through a regulated prescriber, subject to a full clinical assessment. When patients ask you about private routes, the full Wegovy treatment overview on the nume site explains the private eligibility pathway clearly.

Absolute contraindications include a personal or family history of medullary thyroid carcinoma or MEN2 syndrome; Wegovy should also not be used in pregnancy, by those who are breastfeeding, or by those actively trying to conceive. Prescribers should flag these at assessment and document discussions.

How the titration schedule works (and where it now reaches

The standard pathway starts at 0.25mg weekly for four weeks, then steps through the 0.5mg dose, which is the second stage of the titration schedule, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose) each step taken at approximately four-week intervals. The graduated approach is designed to allow the gastrointestinal system to adjust; nausea and other GI effects are most pronounced early and after dose increases, then typically settle within one to two weeks. Patients should be counselled that side effects at initiation don't predict the maintenance experience.

In January 2026 the MHRA extended approval to a 7.2mg maintenance dose, and a dedicated single-dose 7.2mg pen received approval on 14 April 2026, relevant for patients who have not reached target weight loss at 2.4mg. The MHRA's announcement on the 7.2mg pen confirms this is licensed for adults with obesity (BMI ≥30) and that the full titration schedule still begins at 0.25mg. The highest licensed dose should only be considered under clinical supervision, and pen-format availability should be confirmed at the point of prescribing.

The injection can be administered into the abdomen, thigh or upper arm; sites should be rotated. Pens are refrigerated between 2–8°C, the kind of routine detail worth mentioning to patients who commute or travel, since room-temperature storage windows are limited and spelled out in the Patient Information Leaflet rather than this summary. Patients often manage the routine better when they build it into something fixed, like checking the pen is in the fridge door the night before their weekly dose day.

Selecting the right patients: weighing benefit against individual risk

GLP-1-based weight management works best when it is part of a broader programme. The NICE recommendation is explicitly tied to specialist service delivery with multidisciplinary support, not medication alone. For patients you are considering for private referral or private prescription, the same principles apply: realistic expectations, dietary guidance, activity support and regular clinical review matter alongside the pharmacology.

Patient selection involves more than BMI. A clear history of pancreatitis requires careful consideration; the MHRA Drug Safety Update of 29 January 2026 reinforced acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines, with the key warning symptom being severe, persistent abdominal pain radiating to the back. Prescribers should ensure patients know to seek urgent medical assessment if this occurs. Gallbladder disease, a personal history of diabetic retinopathy and concomitant oral contraceptive use (where absorption may be affected) are all areas requiring assessment and patient counselling.

For patients who have previously tried and not responded adequately to a lower dose, or who are considering switching from tirzepatide, the clinical picture should be reviewed in full rather than assuming a direct dose equivalence. Patients asking about semaglutide more broadly (including how it compares with tirzepatide) can be directed to the semaglutide treatment page for patient-level information, or to the Wegovy eligibility section for criteria detail.

Communicating the private pathway to patients honestly

Many patients asking about Wegovy have already done significant research. They may ask whether the NHS route is realistic for them, what private treatment costs, and how to tell a legitimate provider from an unverified one. These are good questions and they deserve straight answers.

On NHS access: NICE TA875 restricts semaglutide to specialist weight management services with multidisciplinary care, and NHS waiting lists for those services can be long. Patients who do not meet NHS criteria or who cannot wait may consider private prescription through a GPhC-registered online pharmacy. When recommending this route, advise patients to verify any provider on the GPhC pharmacy register before sharing personal or clinical information. Providers operating with a clinical assessment and a GPhC-registered Independent Prescriber are the standard to look for. Patients starting out can read the guide to Wegovy's first dosing phase to understand what the early weeks of private treatment typically involve, and those who want to see how the programme develops can continue with the overview of Wegovy's second dosing phase before making any decisions.

You may find it helpful to know that at nume (at nume) every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day, and treatment is dispatched with free next-working-day tracked delivery once clinically approved. Patients who want clinical oversight without a waiting list can start a free consultation. There are no subscriptions, and repeat orders are clinically re-reviewed each time.